Article
Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M wor
Rating:
0.0
Views:
188
Likes:
1
Library:
1
Apellis $APLS is one step closer to catching its rival for the rare blood disorder PNH. The Waltham, MA-based biotech announced that the FDA has begun priority review for its experimental medicine pegcetacoplan after the drug beat Alexion's blockbuster Soliris in a head-to-head Phase III. Regulators have set a PDUFA
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value